Aliko Scientific SA (Euronext Growth Paris: ALIKO) announced a Memorandum of Understanding with BioBrasil to create a joint venture, Aliko Scientific Brasil Ltda, in which Aliko will hold 51 % and BioBrasil 49 %.
The JV will develop and industrial‑scale manufacture FISH (Fluorescence In Situ Hybridization) probes for global diagnostics and research markets, initially using BioBrasil’s existing manufacturing infrastructure, technical capabilities and regulatory certifications, with a possible later move to a dedicated independent production facility.
BioBrasil will have an option for distribution rights in Brazil and Mercosur; Aliko will retain exclusive international distribution rights outside Brazil. Governance will include a board with representatives from both parties, a CEO and CFO appointed by Aliko, and a CSO and COO appointed by BioBrasil.
Management estimates a nine‑month time‑to‑market for the JV, subject to definitive agreements and regulatory approvals covering production setup, validation and certification. The MOU forms the basis for negotiating definitive agreements on business plan, financing, operational framework, governance, IP protection and long‑term commercial arrangements.
Aliko Scientific has a market capitalisation of $28.6 million and reported revenue growth of 81 % over the last twelve months. Analysts from InvestingPro anticipate continued sales growth and consider the stock potentially undervalued.
In a separate announcement, Aliko Scientific Group signed a distribution agreement for its Urine24 bladder‑cancer screening test with Italian distributor Naturneed. Naturneed will use its network of 25 key‑account managers to distribute the test across hospitals, urology clinics and specialist physicians throughout Italy.
BioBrasil is a Brazil‑based molecular biology company specializing in molecular probes and diagnostic solutions. Aliko Scientific, formerly Ikonisys SA, is headquartered in Paris and operates through subsidiaries including Ikonisys Inc. and Hospitex International.
